Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 63-69, October 2004

Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population

  • Yoshiharu Tokuyama

      Affiliations

    • Diabetes Center, Chiba Central Medical Center, 1835-1 Kasori, Wakaba-ku, Chiba 264-0017, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-43-232-3691; fax: +81-43-232-9100.
  • ,
  • Kana Matsui

      Affiliations

    • Division of Clinical Department, Research and Development Center, BML Inc., Kawagoe, Japan
  • ,
  • Toru Egashira

      Affiliations

    • Division of Clinical Department, Research and Development Center, BML Inc., Kawagoe, Japan
  • ,
  • Osamu Nozaki

      Affiliations

    • Diabetes Center, Chiba Central Medical Center, 1835-1 Kasori, Wakaba-ku, Chiba 264-0017, Japan
  • ,
  • Toshiharu Ishizuka

      Affiliations

    • Diabetes Center, Chiba Central Medical Center, 1835-1 Kasori, Wakaba-ku, Chiba 264-0017, Japan
  • ,
  • Azuma Kanatsuka

      Affiliations

    • Diabetes Center, Chiba Central Medical Center, 1835-1 Kasori, Wakaba-ku, Chiba 264-0017, Japan

Received 25 November 2003; received in revised form 27 January 2004; accepted 10 February 2004. published online 19 August 2004.

Abstract 

To address the possibility that the partial disruption of Glucagon-like peptide-1 (GLP-1) signaling could cause diabetes, we tried to detect the mutation in GLP-1 receptor (GLP-1R) gene in the population with type 2 diabetes. Genomic DNA was extracted from 36 unrelated Japanese type 2 diabetic subjects and directly sequenced for the GLP-1R gene. For the detected polymorphisms, 791 patients with type 2 diabetes and 318 controls were screened by polymerase chain reaction-restricted fragment length polymorphism and association study was carried out. Five missense and four silent variants were detected in the GLP-1R gene. There were no significant differences in the frequencies of Pro7Leu, Arg44His and Leu260Pro polymorphism between the diabetic and control groups. And also there were no significant differences in body mass index (BMI), onset age and fasting IRI among the wild type, heterozygote and homozygote of these variants in diabetic patients. Thr149Met mutation was detected in one case among 791 type 2 diabetes patients, but not in control subjects. The patient with this mutation exhibited impairment of both insulin secretion, insulin sensitivity and glucose effectiveness, which may be partially explained by Thr149Met mutation in GLP-1R, though family linkage analysis and function analysis remain to be examined.

Keywords:  Glucagon-like peptide-1, Glucagon-like peptide-1 receptor, Type 2 diabetes, Missense mutation, Minimal model analysis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0168-8227(04)00049-X

doi:10.1016/j.diabres.2004.02.004

Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 63-69, October 2004